Related Experiment Video
Updated: May 1, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Is glyburide safe in pregnancy?
Żaneta Kimber-Trojnar, Beata Marciniak, Jolanta Patro-Malysza
1Chair and Department of Obstetrics and Perinatology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland. zkimber@poczta.onet.pl.
Current Pharmaceutical Biotechnology
|April 12, 2014
Summary
Gestational diabetes mellitus (GDM) management seeks alternatives to insulin. Glyburide shows promise, but data on its placental transfer and safety for pregnant women remain contradictory, necessitating further research.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Neonatal Medicine
Background:
- Hyperglycemia during pregnancy, or gestational diabetes mellitus (GDM), poses risks for neonatal complications.
- Current GDM management often relies on insulin, which has drawbacks.
- Glyburide is an alternative oral medication, but its use in pregnancy is debated due to conflicting safety data.
Purpose of the Study:
- To review the pharmacokinetics, pharmacodynamics, and placental transfer of glyburide.
- To analyze clinical studies on glyburide's efficacy and safety in treating GDM.
- To highlight the need for further research on glyburide's transplacental transport.
Main Methods:
- Focused review of existing literature on glyburide.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Examination of clinical trial results concerning GDM treatment.
Main Results:
- Glyburide's use in GDM is supported by some studies, but concerns about placental transfer persist.
- Conflicting data exist regarding the risks and benefits of glyburide compared to insulin.
- Current recommendations on glyburide use in pregnancy are inconsistent.
Conclusions:
- Further rigorous research is required to clarify glyburide's transplacental transport.
- Evidence-based recommendations for glyburide use in GDM treatment are needed.
- Understanding glyburide's placental transfer is crucial for safe clinical application.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
01:20Pathophysiology of Diabetes
3.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K